Abstract
How to specifically target oncogenic KRAS-driven cancers while sparing normal tissues remains an unmet need in cancer therapy. In this issue of JEM, Jiang et al. (2022. J. Exp. Med.https://doi.org/10.1084/jem.20210739) leveraged KRAS-induced iron addiction in cancer cells to design a clever drug delivery approach to enable selective inhibition of KRAS signaling in mutant KRAS tumors but not in normal tissues, offering a new strategy for treating this largely incurable disease.
Original language | English (US) |
---|---|
Article number | e20212166 |
Journal | Journal of Experimental Medicine |
Volume | 219 |
Issue number | 4 |
DOIs |
|
State | Published - Apr 4 2022 |
ASJC Scopus subject areas
- General Medicine